The invention provides antibodies which specifically bind to DR5 receptor. The anti-DR5 antibodies optionally contain CDR sequences identified using phage-display techniques. The DR5 antibodies can be used, for example, in methods where a modulation of the biological activities of Apo-2L and/or Apo-2L receptors is desired, including cancer and immune-related conditions.